AbCellera Biologics Inc. (ABCL) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

9/25

Growth 2 Margin 1 Expansion 3 Platform 1 Financial 2

latest quarter score

Earnings Reports

9
AbCellera (ABCL) Q2 2026: $110M Upfront from Vertex and Jazz Deals Bolsters $675M Liquidity Runway
August 06, 2026
8
AbCellera (ABCL) Q1 2026: $655M Liquidity Anchors Push Toward $6B Menopause Market
May 12, 2026
10
AbCellera (ABCL) Q4 2025: Pipeline Expands to 4 Clinical Programs, $700M Liquidity Extends Runway
February 25, 2026
8
AbCellera (ABCL) Q3 2025: $680M Liquidity Anchors Clinical Pipeline Transition
November 07, 2025
12
AbCellera (ABCL) Q2 2025: $750M Liquidity Powers Clinical Pipeline Pivot
August 08, 2025
8
AbCellera (ABCL) Q1 2025: $43M R&D Spend Accelerates Clinical Pipeline Transition
July 05, 2025
AbCellera Biologics (ABCL) FY 2024: $840M Liquidity Supports Transition to Clinical-Stage Biotech
February 27, 2025
AbCellera (ABCL) Q3 2024: $32M R&D Impairment Marks Pipeline Prioritization Pivot
November 04, 2024
AbCellera (ABCL) Q2 2024: Research Fee Revenue Falls 30% as Internal Pipeline Becomes Priority
August 06, 2024
AbCellera (ABCL) Q1 2024: $725M Liquidity Anchors Pipeline and Platform Buildout
May 07, 2024
AbCellera (ABCL) Q4 2023: Royalty Rate Rises to 4.3% as Internal Pipeline Drives Strategic Shift
February 20, 2024
11
AbCellera (ABCL) Q3 2023: R&D Spend Climbs 40% as Internal Pipeline Advances Toward 2025 INDs
November 02, 2023
AbCellera (ABCL) Q2 2023: $222M Government Infusion Strengthens Pre-Partnered Pipeline and Vertical Integration
August 03, 2023
AbCellera (ABCL) Q1 2023: R&D Spend Jumps $26M as Platform Integration Deepens
May 04, 2023
AbCellera (ABCL) Q4 2022: Royalty Rate Rises to 4.1% as Diversified Pipeline Expands
February 21, 2023

Browse all companies